Skip to main content


Sanford Health Opens I-SPY 2 Clinical Trial for Breast Cancer Patients

Feb 05, 2021 10:16AM ● By Med Magazine
Sanford Health has a new option for patients diagnosed with breast cancer. The I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And molecular anaLysis 2), is an adaptive platform clinical trial, created to identify successful treatments for Stage II/III breast cancer while minimizing the number of required participants and time required to evaluate the treatments. In essence, it is the most efficient clinical trial platform available.

I-SPY 2 is a novel treatment study for locally advanced breast cancer.  It is now available at Sanford USD Medical Center in Sioux Falls, and 20 leading cancer centers across the United States. The collaboration allows potential treatments and drugs to be evaluated in a fashion that is faster than traditional studies, and aims to offer access to trial participation to a greater number of patients.

Building upon the original I-SPY 1 clinical trial. I-SPY 2 has screened over 3000 patients and has graduated several promising investigational treatments.

“Sanford Health prides itself on bringing innovative treatment options to our patients,” said Amy Sanford, M.D., an oncologist at Sanford Health. “Our participation in I-SPY 2 is another example of our commitment to leading cancer care discovery, right here in the Upper Midwest, for our patients and others around the world”.

Sanford Health patients who may be interested in enrolling in I-SPY 2, or other clinical trials, should talk with their providers about their options.